STOCK TITAN

Commodore Capital and principals disclose 9.9% holding in PALI

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Commodore Capital and affiliated filers reported beneficial ownership of 9,690,665 shares of Palisade Bio, Inc. common stock, representing 9.9% of the outstanding class as of October 1, 2025. The position consists of 9,332,443 shares plus 358,222 shares issuable upon exercise of a pre-funded warrant; an additional 4,827,492 shares underlying a separate pre-funded warrant were excluded due to a stated 9.99% beneficial ownership limitation. The reporting group includes Commodore Capital LP (investment manager), Commodore Capital Master LP, and principals Robert Egen Atkinson and Michael Kramarz. Filers certify the stake was not acquired to change or influence control.

Positive

  • Sizeable stake disclosed: 9,690,665 shares equals 9.9% ownership, showing material investor interest
  • Transparent mechanics: filing specifies share counts, pre-funded warrant conversion of 358,222 shares, and the 9.99% ownership limit

Negative

  • Beneficial Ownership Limitation (9.99%) restricts immediate increase beyond current 9.9% position
  • Excluded warrants: 4,827,492 shares underlying a pre-funded warrant are not counted, limiting clarity on potential future dilution or accumulation

Insights

Large passive stake disclosed: 9.9% ownership signals significant investor interest.

The reported 9.9% position is sizeable relative to the 96,645,431 shares used for the calculation and could make the filers a meaningful blockholder for Palisade Bio. The position is held by an investment manager and related entities, with voting and dispositive power shared across the group.

Near-term dependencies include the Beneficial Ownership Limitation (9.99%) that caps further immediate economic ownership and the existence of additional excluded pre-funded warrants totaling 4,827,492 shares which could not be counted due to that cap. Watch for any amendment if the filers seek to exceed the limit or disclose plans beyond passive ownership within the next reporting cycle.

Disclosure clarifies ownership mechanics and governance posture.

The filing states the position was not acquired to change or influence control and includes a certification to that effect, which is relevant for governance signalling and potential proxy dynamics. Shared voting/dispositive power indicates coordinated decision-making among the filers rather than a single individual acting alone.

Risks and monitoring points include any future transactions that would require an update to Schedule 13D/G if intent or ownership changes, and whether the group engages in nominations or other governance actions; such developments would likely be reported in subsequent filings within standard SEC timeframes.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Commodore Capital LP
Signature:Michael Kramarz
Name/Title:Managing Partner
Date:10/08/2025
Commodore Capital Master LP
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:10/08/2025
Robert Egen Atkinson
Signature:Robert Egen Atkinson
Name/Title:Authorized Signatory
Date:10/08/2025
Michael Kramarz
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:10/08/2025
Exhibit Information

Exhibit 1: Joint Filing Agreement

Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

PALI Latest News

PALI Latest SEC Filings

PALI Stock Data

328.25M
136.93M
0.24%
5.92%
3.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD